黑料网

Atherosclerosis, characterized by the accumulation of lipid-rich plaques within arterial walls, is a leading cause of cardiovascular diseases, such as myocardial infarction, stroke, and peripheral artery disease. The stability of these plaques is a critical determinant of clinical outcomes, as unstable plaques can rupture, leading to thrombosis and sudden occlusion of the affected artery. In recent years, research has increasingly focused on the role of angiogenesis the formation of new blood vessels in the pathogenesis of atherosclerotic plaque stability. While angiogenesis may seem beneficial for providing nutrients and oxygen to growing plaques, it can also contribute to plaque instability and rupture. Understanding how angiogenesis influences plaque behavior is crucial for developing therapeutic strategies aimed at preventing cardiovascular events [1].

Description

Angiogenesis in atherosclerotic plaques

Angiogenesis in atherosclerosis is primarily driven by the growing metabolic demands of the plaque. As atherosclerotic lesions increase in size, the tissue within the plaque can become hypoxic due to inadequate blood supply. This triggers the release of pro-angiogenic factors, such as vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), and angiopoietins, which stimulate the formation of new blood vessels. The formation of these vessels is an attempt to provide oxygen and nutrients to the growing plaque. However, the newly formed vessels are often structurally abnormal, fragile, and prone to leakage [2].

The angiogenic process in atherosclerotic plaques often occurs in response to the hypoxic and inflammatory environment within the plaque. Inflammatory cells, including macrophages and T lymphocytes, secrete cytokines that further promote angiogenesis. Additionally, matrix metalloproteinases (MMPs) are upregulated, contributing to the remodeling of the extracellular matrix and the formation of new blood vessels.

Impact on plaque stability

The role of angiogenesis in atherosclerotic plaque stability is complex and depends on the nature of the new blood vessels formed. On one hand, angiogenesis can help stabilize plaques by increasing the supply of oxygen and nutrients, which may reduce plaque inflammation and promote healing in the plaque’s outer fibrous cap [3]. A well-vascularized plaque may also have a stronger fibrous cap, which could prevent the plaque from rupturing.

On the other hand, the blood vessels formed within atherosclerotic plaques are often immature and disorganized. These vessels are typically more permeable and prone to rupture, contributing to the instability of the plaque. When these vessels rupture, they can release pro-thrombotic substances, such as tissue factor, into the bloodstream. This can trigger the formation of a clot (thrombus) that obstructs blood flow, resulting in acute ischemic events like myocardial infarction or stroke [4].

Additionally, the presence of angiogenesis can create a vicious cycle, as the new blood vessels supply the plaque with more inflammatory cells, which, in turn, can stimulate further angiogenesis and promote plaque growth. This ongoing process may lead to the formation of larger, more unstable plaques with a higher risk of rupture.

The role of inflammation and extracellular matrix remodeling

Inflammation is a key driver of both angiogenesis and plaque destabilization. The inflammatory environment within the plaque enhances the expression of angiogenic factors such as VEGF, which are produced by both endothelial cells and infiltrating inflammatory cells like macrophages. These pro-inflammatory factors contribute to the formation of fragile blood vessels that are prone to rupture [5].

The extracellular matrix (ECM) also plays a critical role in determining plaque stability. Matrix metalloproteinases (MMPs) degrade the ECM and are involved in both angiogenesis and the destabilization of atherosclerotic plaques. MMPs break down the fibrous cap and the collagen matrix, weakening the structural integrity of the plaque and making it more susceptible to rupture. Additionally, MMPs promote angiogenesis by clearing the path for new blood vessels to form.

Implications for clinical outcomes

The dual role of angiogenesis in atherosclerosis both beneficial and harmful has significant implications for clinical outcomes. On the one hand, improving the blood supply to ischemic regions through angiogenesis could reduce tissue injury and promote healing [6]. On the other hand, excessive or abnormal angiogenesis in atherosclerotic plaques may increase the risk of plaque rupture and the development of acute cardiovascular events.

The key to managing the impact of angiogenesis in atherosclerosis lies in understanding the balance between pro-angiogenic and anti-angiogenic factors. Therapeutic interventions could focus on either promoting angiogenesis in ischemic tissue to improve collateral circulation or inhibiting angiogenesis in plaques to prevent plaque rupture. Current research is exploring the potential of anti-angiogenic therapies that could stabilize plaques and reduce the risk of thrombosis, but such strategies must be carefully balanced to avoid impairing normal vascular healing and regeneration [7,8].

Conclusion

Angiogenesis plays a crucial role in the development and progression of atherosclerosis, influencing plaque stability and the risk of rupture. While angiogenesis can be beneficial by supplying oxygen and nutrients to growing plaques, it can also lead to the formation of fragile, leaky blood vessels that promote plaque destabilization and rupture. The complex interaction between angiogenesis, inflammation, and extracellular matrix remodeling determines the overall stability of the plaque. As research continues, the goal is to develop targeted therapies that can modulate angiogenesis to improve plaque stability without compromising the body's ability to repair damaged tissues. Understanding the mechanisms of angiogenesis in atherosclerosis is vital for improving the prevention and treatment of cardiovascular diseases.

Acknowledgement

None

Conflict of Interest

None

References

1. Ritossa F (1996) Cell Stress Chaperones 1: 97-98.

, ,

2. Hartl FU (1996) Nature 381: 571-579.

, ,

3. Milani A, Basirnejad M, Bolhassani A, Gazali A, Stebbing J, et al. (2019) Immunotherapy 11: 215-239.

, ,

4. De Maio A (1999) Shock 11: 1-12.

, ,

5. Hartl FU, Hayer-Hartl M (2009) Nat Struct Mol Biol 16: 574581.

, ,

6. Dattilo S, Mancuso C, Koverech G, Di Mauro P, Ontario ML, et al. (2015) Immun Ageing 12: 20.

, ,

7. Kampinga HH, Hageman J, Vos MJ, Kubota H, Tanguay RM, et al. (2009) Cell Stress Chaperones 14: 105-111.

, ,

8. Hightower LE, Guidon Jr PT (1989) J Cell Physiol 138: 257-266.

, ,